Cigna Investments’s Haemonetics HAE Stock Holding History

Cigna Investments’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,834	Closed	-$202K	–	760
2021 Q1	$202K	Buy	1,834 +116	+7%	+$14.4K	0.01%	738
2020 Q4	$204K	Buy	+1,718	New	+$185K	0.02%	692
2020 Q3	–	Sell	-2,585	Closed	-$232K	–	687
2020 Q2	$232K	Buy	+2,585	New	+$261K	0.02%	628
2019 Q1	–	Sell	-7,372	Closed	-$738K	–	721
2018 Q4	$738K	Sell	7,372 -2,015	-21%	-$212K	0.06%	230
2018 Q3	$980K	Sell	9,387 -8,529	-48%	-$883K	0.08%	193
2018 Q2	$1.61M	Buy	17,916 +7,060	+65%	+$596K	0.12%	155
2018 Q1	$794K	Sell	10,856 -32	-0.3%	-$2.2K	0.05%	312
2017 Q4	$632K	Hold	10,888	–	–	0.04%	375
2017 Q3	$489K	Sell	10,888 -41	-0.4%	-$1.7K	0.03%	471
2017 Q2	$432K	Sell	10,929 -3,081	-22%	-$127K	0.03%	495
2017 Q1	$568K	Buy	14,010 +388	+3%	+$15.2K	0.04%	406
2016 Q4	$548K	Buy	+13,622	New	+$514K	0.06%	373

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

LCOV

London Company of Virginia Richmond, Virginia $17.5B AUM 29.92% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.97B AUM 15.72% 1-Year Est. Return

Cigna Investments's HAE Position: Q2 2021 in Review

Cigna Investments sold out of Haemonetics (HAE) in Q2 2021, closing a stake of 1,834 shares — an estimated $202K sold.

Cigna Investments first reported a position in HAE in Q4 2016 and held it in 12 quarters. The position peaked at $1.61M in Q2 2018. 258 funds tracked by Wall St. Rank hold HAE as of Q2 2021.

Cigna Investments reported no remaining Haemonetics position as of Q2 2021 after selling out during the quarter.
Cigna Investments sold 1,834 Haemonetics shares in Q2 2021, an estimated $202K.
Cigna Investments first reported a position in Haemonetics in Q4 2016 and held it in 12 quarters.
Cigna Investments's Haemonetics position peaked at $1.61M in Q2 2018.
258 funds tracked by Wall St. Rank held Haemonetics as of Q2 2021.

Based on Cigna Investments's 13F filing for Q2 2021, filed 10 Aug 2021.